Evidence map›Paper›PMID 35368066›Full record

ArticleNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2023

Tobacco Smoking and Risk of SARS-CoV-2 Infection and Disease Severity Among Adults in an Integrated Healthcare System in California.

Kelly C Young-Wolff, Natalie Slama, Stacey E Alexeeff, Lori C Sakoda, Renee Fogelberg, Laura C Myers, Cynthia I Campbell, Alyce S Adams, Judith J Prochaska

Open access · bronzeAbstract read
In one paragraph

Article in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. The Impact of the COVID-19 Pandemic on Nicotine Use: What Have We Learned?Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2023
    Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Kelly C Young-WolffDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.ORCID 0000-0002-6177-534X
Natalie SlamaDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.ORCID 0000-0002-4930-1061
Stacey E AlexeeffDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Lori C SakodaDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Renee FogelbergRichmond Medical Center, Kaiser Permanente Northern California, Richmond, CA, USA.
Laura C MyersDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Cynthia I CampbellDivision of Research, Kaiser Permanente Northern California, Oakland, CA, USA.
Alyce S AdamsStanford Cancer Institute, Stanford University, Stanford, CA, USA.
Judith J ProchaskaStanford Prevention Research Center, Stanford University, Stanford, CA, USA.ORCID 0000-0001-7925-326X
Kaiser Permanente · USStanford University · USKaiser Permanente Richmond Medical Center · US

Funding

Translational Research Core - Health Engagement & Action Translational (HEAT)P30DK092924 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI Alyce Sophia Adams, HILARY Kessler SELIGMAN · 2011 to 2026
$9.2M
Identifying Risk Factors for Prenatal Substance and Polysubstance UseK01DA043604 · NIDA · KAISER FOUNDATION RESEARCH INSTITUTE · PI YOUNG-WOLFF, KELLY CORINNE · 2017 to 2021
$907k
NIDA NIH HHS K01 DA043604NIDDK NIH HHS P30 DK092924
6 · The paper itself

Abstract

introductionThe relationship between tobacco smoking status and SARS-CoV-2 infection and coronavirus disease 2019 (COVID-19) severity is highly debated. We conducted a retrospective cohort study of >2.4 million adults in a large healthcare system to evaluate whether smoking is associated with SARS-CoV-2 infection and disease severity. AIMS AND

methodsThis retrospective cohort study of 2,427,293 adults in KPNC from March 5, 2020 (baseline) to December 31, 2020 (pre-vaccine) included smoking status (current, former, never), socio-demographics, and comorbidities from the electronic health record. SARS-CoV-2 infection (identified by a positive PCR test) and COVID-19 severity (hospitalization, ICU admission or death ≤ 30 days of COVID-19 diagnosis) were estimated in time-to-event analyses using Cox proportional hazard regression models adjusting for covariates. Secondary analyses examined COVID-19 severity among patients with COVID-19 using logistic regression.

resultsDuring the study, 44,270 patients had SARS-CoV-2 infection. Current smoking was associated with lower adjusted rates of SARS-CoV-2 infection (aHR = 0.64 95% CI: 0.61-0.67), COVID-19-related hospitalization (aHR = 0.48 95% CI: 0.40-0.58), ICU admission (aHR = 0.62 95% CI: 0.42-0.87), and death (aHR = 0.52 95% CI: 0.27-0.89) than never-smoking. Former smoking was associated with a lower adjusted rate of SARS-CoV-2 infection (aHR = 0.96 95% CI: 0.94-0.99) and higher adjusted rates of hospitalization (aHR = 1.10 95% CI: 1.03-1.08) and death (aHR = 1.32 95% CI: 1.11-1.56) than never-smoking. Logistic regression analyses among patients with COVID-19 found lower odds of hospitalization for current versus never-smoking and higher odds of hospitalization and death for former versus never-smoking.

conclusionsIn the largest US study to date on smoking and COVID-19, current and former smoking showed lower risk of SARS-CoV-2 infection than never-smoking, while a history of smoking was associated with higher risk of severe COVID-19. IMPLICATIONS: In this cohort study of 2.4 million adults, adjusting for socio-demographics and medical comorbidities, current tobacco smoking was associated with a lower risk of both SARS-CoV-2 infection and severe COVID-19 illness compared to never-smoking. A history of smoking was associated with a slightly lower risk of SARS-CoV-2 infection and a modestly higher risk of severe COVID-19 illness compared to never-smoking. The lower observed COVID-19 risk for current versus never-smoking deserves further investigation. Results support prioritizing individuals with smoking-related comorbidities for vaccine outreach and treatments as they become available.

Indexed as

COVID-19Delivery of Health Care, IntegratedAdultCaliforniaCohort StudiesCOVID-19 TestingHospitalizationHumansPatient AcuityRetrospective StudiesSARS-CoV-2Tobacco Smoking

Identifiers

PMID35368066
PMCPMC9825324
OpenAlexW4225435553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.